Bioequivalence Study of Two Orally Disintegrating Risperidone Formulations, Risperdal OD$^{(R)}$ Tablet 1mg and Risperdal Quicklet$^{(R)}$ Tablet 1mg in Healthy Korean Volunteers

건강한 한국인 자원자에서 리스페리돈 구강붕해 제제인 리스페달오디$^{(R)}$정 1mg과 리스페달 퀵릿$^{(R)}$정 1mg의 생물학적동등성 연구

  • Kang, Ga-Eun (Department of Pharmacology, Chonnam National University Medical School) ;
  • Kim, Jin (Division of Clinical Pharmacology, Chonnam National University Hospital) ;
  • Bae, Kyung-Yeol (Department of Psychiatry, Chonnam National University Medical School) ;
  • Shin, Hee-Young (Department of Biomedical Science, Chonnam National University Medical School) ;
  • Jeong, Seong-Wook (Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School) ;
  • Yoon, Jin-Sang (Department of Psychiatry, Chonnam National University Medical School) ;
  • Kim, Jong-Keun (Department of Pharmacology, Chonnam National University Medical School)
  • 강가은 (전남대학교 의과대학 약리학교실) ;
  • 김진 (전남대학교병원 임상약리실) ;
  • 배경열 (전남대학교 의과대학 정신과학교실) ;
  • 신희영 (전남대학교 의과대학 의생명과학교실) ;
  • 정성욱 (전남대학교 의과대학 마취통증의학교실) ;
  • 윤진상 (전남대학교 의과대학 정신과학교실) ;
  • 김종근 (전남대학교 의과대학 약리학교실)
  • Received : 2011.05.19
  • Accepted : 2011.06.22
  • Published : 2011.06.30

Abstract

Background: Risperidone is one of the atypical antipsychotic drugs that have effectiveness in the management of a range of psychiatric illnesses. Orally disintegrating (OD) formulations of risperidone that rapidly dissolve in the mouth, prior to swallowing without water have been developed to overcome any problems related to swallowing and improve acceptability. The goal of this study was to evaluate the bioequivalence of Risperdal OD$^{(R)}$ tablet 1mg and Quicklet$^{(R)}$ tablet 1mg Methods: This randomized, open-label, 2-way crossover trial was conducted in 36 healthy male volunteers that received OD risperidone tablet, either the reference formulation (Risperdal Quicklet$^{(R)}$tablet 1mg), or the test formulation (Risperdal OD$^{(R)}$ tablet 1mg), each in a single administration. Blood samples were obtained during a 24-hour period after dosing. Plasma was analyzed for risperidone by a validated LC-MS/MS. Adverse events were monitored by safety assessments including clinical interview by clinician. Pharmacokinetics were calculated by noncompartmental analysis and compared between two formulations Results: A total of 36 male volunteers (mean age, 24.2 years; height 174.5 cm; weight 67.6 kg) completed the study. The ANOVA showed no significant effect of sequence, formulation and period of Ln ($AUC_{last}$) and Ln ($C_{max}$). The 90 % confidence intervals for the mean treatment ratios of the Ln (AUClast) and Ln ($C_{max}$) were Ln 0.96 ~ Ln 1.12, Ln 0.97 ~ Ln 1.16, respectively. No serious adverse events were caused by both formulations. Conclusion: In this study, a single administration of Risperdal OD$^{(R)}$ tablet 1mg was bioequivalent to a single administration of Risperdal Quicklet$^{(R)}$ tablet 1mg.

Keywords

References

  1. 대한신경정신의학회. 신경정신의학. 2nd ed. 중앙문화사, 서울. 2005.
  2. Lechat P, Vermeulen D, Heald D. Risperidone QuicksolvTM/QuickletTM pharmacokinetics in humans. A summary of the pharmacokinetic data on the bioavailability/bioequivalence of Quicksolv TM/ Quicklet TM and commercially available tablets. Johnson & Johnson Pharmaceuticla Research & Development, a division of Janssen Pharmaceutica NV, 2001.
  3. US Food and Drug Administration, CDER Guidancd for industry. Orally disintegrating tablets. 2008.
  4. Hirani JJ, Rathod DA, Vadalia KR. Orally disintegrating tablets: A review. Tropical Journal of Pharmaceutical Research, 2009; 8(2):161-172.
  5. Sastry SV, Nyshadham JR, Fix JA. Recent tehnological advances in oral drug delivery a review. Pharm Sci Technolo Today, 2003;3(4):138-145.
  6. 식품의약품안전청 고시 제 2008-22호, 생물학적동등성시험기준.
  7. van Schaick EA, Lechat P, Remmerie BM, Ko G, Lasseter KC, Mannaert E. Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clin Ther, 2003; 25(6):1687-1699. https://doi.org/10.1016/S0149-2918(03)80163-7
  8. Cho HY, Park EJ, Kang HA, Baek SH, Lee S, Park CH, Moon JD, Lee YB. Bioequivalence of Rispen Tablet to Risperdal Tablet(Risperidone 2mg). J Kor Pharm Sci, 2004;13:271-277.
  9. Machin D, Campbell MJ. Design of studies for medical research. John Wiley & Sons Ltd, L-ondon. 2005.
  10. Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol, 1991;29(1): 1-8.
  11. Bhatt J, Subbaiah G, Singh S. Liquid chroma tography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma. Rapid Commun Mass Spectrom, 2006;20(14):2109-2114. https://doi.org/10.1002/rcm.2537
  12. Huang MZ, Shentu JZ, Chen JC, Liu J, Zhou HL. Determination of risperidone in human plasma by HPLC-MS/MS and its application to a pharmacokinetic study in Chinese volunteers. J Zhejiang Univ Sci B, 2008;9(2): 114-120. https://doi.org/10.1631/jzus.B0710439
  13. 리스페달 퀵릿 정 상세허가정보. (주)한국얀센2009
  14. Hauschke D, Steinijans V, Pigeot I. Bioequivalence studies in drug development: methods and applications. John Wiley & Sons Inc, London. 2007.
  15. 권광일, 김옥희, 김종국, 김주일, 배균섭, 사홍기, 이용복, 이화정, 최선옥. 생물학적동등성의 이해. 신일상사, 서울. 2006.